医学
急性失代偿性心力衰竭
危险系数
内科学
置信区间
心力衰竭
混淆
重症监护医学
作者
Masaki Nakagaito,Teruhiko Imamura,Shuji Joho,Ryuichi Ushijima,Makiko Nakamura,Koichiro Kinugawa
出处
期刊:International Heart Journal
[International Heart Journal Association]
日期:2021-07-30
卷期号:62 (4): 885-890
被引量:9
摘要
Sodium-glucose cotransporter 2 inhibitor (SGLT2i) reduces mortality and morbidity in patients with chronic heart failure (HF). However, the clinical implication of SGLT2i therapy in patients with acute decompensated HF remains uncertain. We prospectively studied 86 type 2 diabetic mellitus (T2DM) patients (71.8 ± 12.1 years, 55 men) who were hospitalized for acute decompensated HF and received SGLT2i during the index hospitalization. Among the patients, 56 continued SGLT2i at discharge and 30 did not. The continued group experienced fewer HF re-hospitalizations than the discontinued group (24% versus 39%, P = 0.008) with a hazard ratio of 0.29 (95% confidence interval 0.10-0.85) adjusted for other significant potential confounders. In conclusion, long-term SGLT2i therapy might prevent unplanned HF re-hospitalization in patients with T2DM and acute decompensated HF.
科研通智能强力驱动
Strongly Powered by AbleSci AI